Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Raptech who wrote (1734)	11/25/1998 8:24:00 PM
From: Walter Morton	Read Replies (2) \| Respond to of 2742

At least our stock would be controlled by a company that has marketing and management skill to complement CIST's research & development skills. The stock may have a better chance of increasing in value.

To: Raptech who wrote (1734)	11/30/1998 8:02:00 PM
From: Walter Morton	Read Replies (2) \| Respond to of 2742

So, you don't want ENDG nor BIOI to merge or buy CIST because of the one for 11 stock exchange? Did you consider CIST's book value? That may get us one share for six shares of CIST. These companies have had sales in the millions -- $9 million and $20 million respectively. They seem to know how to market their products... something CIST admits to not trying to do: Message 6536360 LOOK AT THESE COMPANIES: quicken.com quicken.com endogen.com biosource.com I don't expect that we would lose much of the value of our stock. We would just have fewer shares. So, I think it comes down to this: Would you buy ENDG or BIOI if they had a million dollars guaranteed to come in (from an Immunex settlement) and a potential $30+ Million deal with the largest vaccine company in the world?